DBV Technologies S.A. Share Price & Technical Analysis
DBVT · $17.41 (+5.26%)
Healthcare / Biotechnology
$17.41
+5.26%
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobul…
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-6% return in Jun, -8% avg return in past 3 year Jun month.
-9% return in 2026, 152% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 14% | -4% | -1% | -1% | -10% | -6% | – | – | – | – | – | – | -9% |
| 25 | 27% | 10% | 66% | 41% | -5% | 14% | -9% | 3% | 5% | 34% | -9% | 43% | 221% |
| 24 | -5% | -11% | -6% | -13% | -15% | -33% | 25% | -10% | -22% | 14% | 388% | -18% | 291% |
| 23 | -19% | 4% | 13% | -12% | 30% | -5% | -21% | -3% | -16% | -26% | -29% | 27% | -56% |
| 22 | -6% | -13% | 19% | -19% | 15% | 65% | 9% | -18% | -10% | -12% | -16% | 11% | 24% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$965.04M
P/E ratio
—
52W high
$26.18
52W low
$8.50
Volume
9,89,858
Beta
-0.22
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is DBV Technologies S.A. share price today?
- DBV Technologies S.A. (DBVT) last traded around $17.41 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does DBVT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for DBVT. Download the app for real-time alerts.
- How can I analyze DBV Technologies S.A. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.